{"id":51177,"date":"2025-12-17T22:15:15","date_gmt":"2025-12-17T14:15:15","guid":{"rendered":"https:\/\/flcube.com\/?p=51177"},"modified":"2025-12-17T22:15:17","modified_gmt":"2025-12-17T14:15:17","slug":"hansoh-licenses-egfr-drug-aumolertinib-to-glenmark-for-1b-in-milestones","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51177","title":{"rendered":"Hansoh Licenses EGFR Drug Aumolertinib to Glenmark for $1B+ in Milestones"},"content":{"rendered":"\n

Jiangsu Hansoh Pharmaceutical Co. Ltd.<\/strong> (HKG: 3692<\/a>) entered into an exclusive license, collaboration, and distribution agreement with Glenmark Specialty S.A.<\/strong> for aumolertinib<\/strong>, a third\u2011generation EGFR\u2011TKI<\/strong> for non\u2011small cell lung cancer (NSCLC). Glenmark gains rights across Middle East, Africa, Southeast\/South Asia, Australia, New Zealand, Russia\/CIS, and Caribbean<\/strong> territories. Hansoh receives an upfront payment plus milestones potentially exceeding $1 billion<\/strong> and tiered royalties.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Component<\/th>Details<\/th><\/tr><\/thead>
Product<\/strong><\/td>Aumolertinib (third\u2011generation EGFR\u2011TKI)<\/td><\/tr>
Licensor<\/strong><\/td>Jiangsu Hansoh Pharmaceutical (3692.HK)<\/td><\/tr>
Licensee<\/strong><\/td>Glenmark Specialty S.A.<\/td><\/tr>
Territories<\/strong><\/td>Middle East, Africa, Southeast\/South Asia, Australia, New Zealand, Russia\/CIS, Caribbean<\/td><\/tr>
Financial Terms<\/strong><\/td>Upfront payment + milestones >$1B + tiered royalties<\/td><\/tr>
Innovation<\/strong><\/td>China\u2019s first domestically developed third\u2011generation EGFR\u2011TKI<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Aumolertinib Regulatory Approvals<\/h2>\n\n\n\n
Approval Date<\/th>Indication<\/th>Region<\/th><\/tr><\/thead>
Mar\u202f2020<\/strong><\/td>T790M\u2011positive locally advanced\/metastatic NSCLC (post\u2011EGFR\u2011TKI)<\/td>China<\/td><\/tr>
Dec\u202f2021<\/strong><\/td>First\u2011line EGFR exon 19 deletion\/L858R NSCLC<\/td>China<\/td><\/tr>
Mar\u202f2025<\/strong><\/td>Unresectable locally advanced NSCLC post chemoradiotherapy<\/td>China<\/td><\/tr>
May\u202f2025<\/strong><\/td>Adjuvant Stage\u202fII\u2011IIIB NSCLC post\u2011resection<\/td>China<\/td><\/tr>
Jun\u202f2025<\/strong><\/td>Aumseqa brand approved<\/td>UK (MHRA)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity & Strategic Context<\/h2>\n\n\n\n